

2nd Global Congress on Vaccines 2008

Procedia in Vaccinology Volume 1

**Boston, Massachusetts, USA
7 – 9 December 2008**

Editors:

R. Spier

ISBN: 978-1-62748-767-2

Printed from e-media with permission by:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571



Some format issues inherent in the e-media version may also appear in this print version.

Copyright© by Elsevier B.V.
All rights reserved.

Printed by Curran Associates, Inc. (2014)

For permission requests, please contact Elsevier B.V.
at the address below.

Elsevier B.V.
Radarweg 29
Amsterdam 1043 NX
The Netherlands

Phone: +31 20 485 3911
Fax: +31 20 485 2457

<http://www.elsevierpublishingsolutions.com/contact.asp>

Additional copies of this publication are available from:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571 USA
Phone: 845-758-0400
Fax: 845-758-2634
Email: curran@proceedings.com
Web: www.proceedings.com

TABLE OF CONTENTS

CONFERENCE OVERVIEW	1
<i>Ray Spier</i>	
SINGLE HLA-A2.1 RESTRICTED EPITOPE DNA VACCINE IN RABBITS	4
<i>Jiafen Hu, Todd D. Schell, Xuwen Peng, Nancy M. Cladel, Karla K. Balogh, Neil D. Christensen</i>	
IMMUNOME-DERIVED EPITOPE-DRIVEN VACCINES (ID-EDV) PROTECT AGAINST VIRAL OR BACTERIAL CHALLENGE IN HUMANIZED MICE	15
<i>Lenny Moise, Matt Ardito, Joe Desrosiers, Jill Schriewer, Mark Buller, Sharon E. Frey, Stephen H. Gregory, Steven F. Moss, Jinhee Lee, Hardy Kornfeld, Bill Martin, Anne S. De Groot</i>	
VAXIGN: A WEB-BASED VACCINE TARGET DESIGN PROGRAM FOR REVERSE VACCINOLOGY	23
<i>Zuoshuang Xiang, Yongqun He</i>	
FERRET MODEL OF AVIAN INFLUENZA DEMONSTRATES DOSE AND STRAIN DEPENDANT PATHOLOGY AND VIRAL LOAD IN BRAIN	30
<i>Rc Layton, P Armijo, L Myers, J Knight, N Donart, K Sannes-Lowery, L Blyn, A Gigliotti, S Kunder, N Fomukong, K Harrod, F Koster</i>	
NEW PERSPECTIVES IN VACCINATION AND IMMUNOTHERAPIES FOR HBV INFECTIONS	35
<i>Emilio D'Ugo, Claudio Argentini, Stefania Catone, Andrea Canitano, Roberto Giuseppetti, Reinhard Gluck, Maria Rapicetta</i>	
DEVELOPMENT OF SENDAI VIRUS-BASED VACCINES TO PREVENT PEDIATRIC RESPIRATORY VIRUS INFECTIONS	41
<i>Julia L. Hurwitz, Jerry L. Shenep, Charles J. Russell, Allen Portner</i>	
DESIRED IMMUNE RESPONSE CHARACTERISTICS IN AN RSV VACCINE: WHAT INFANTS TELL US	45
<i>Jennifer L. Reed, Luis Avendaño, Luis Velozo, Robert C. Welliver Sr.</i>	
GLOBAL HIV VACCINE RESEARCH CRYOREPOSITORY-GHRC	49
<i>Anja Germann, Christopher H. P. Durst, Frank R. Ihmig, Stephen G. Shirley, Uwe Schön, Stefanie Koch, Julia Schulz, Jochen Schmidt, Heiko Zimmermann, Andreas Meyerhans, Hagen Von Briesen</i>	
SHIGELLA SONNEI OLIGOSACCHARIDE-PROTEIN CONJUGATES	63
<i>Joanna Kubler-Kielb, Evgeny Vinogradov, Chris Mocca, Chunyan Guo, Rachel Schneerson, John B. Robbins</i>	
SIMULATION MODEL FOR COMPARING THE COSTS AND EFFECTIVENESS OF DIFFERENT PNEUMOCOCCAL CONJUGATE VACCINES	67
<i>Philippe De Wals, Béatrice Poirier, Geneviève Petit, Lonny Erickson, Jacques Pépin</i>	
PERTUSSIS IN ADULTS WITH PERSISTENT COUGH: A PROSPECTIVE FOLLOW UP STUDY IN PRIMARY CARE	73
<i>Joan Puig-Barberà, Javier Díez-Domingo, Eliseo Pastor-Villalba, Juan Garcia-Lomas, Isabel Huertas-Zarco, Santiago Pérez-Hoyos</i>	
RECOMBINANT BACULOVIRUSES AS VEHICLES FOR PRESENTATION AND ADJUVANCY OF ANTIGENS FOR THE DEVELOPMENT OF NEW TUBERCULOSIS CANDIDATE VACCINES	81
<i>Paula Molinari, Verónica Bianco, Andrea Peralta, María José Gravisaco, Gabriel Morón, Fabiana Bigi, Oscar Taboga</i>	
INVESTIGATION OF HUMORAL AND CELLULAR IMMUNITY OF DAIRY CATTLE AFTER ONE OR TWO YEAR OF VACCINATION WITH A PHASE I COXIELLA VACCINE	85
<i>A Rodolakis, P Clement, D Cochonneau, F Beaudeau, P Sarradin, R Guatteo</i>	
IMPROVEMENTS IN THE PREVENTION AND TREATMENT OF ANTHRAX INFECTION	89
<i>Dennis M. Klinman, Debra Tross</i>	
YERSINIA PESTIS LIVE VACCINE WITH IMPROVED CHARACTERISTICS	97
<i>V. A. Feodorova, L. N. Pan'Kina, E. P. Savostina, O. S. Kuznetsov, N. P. Konnov, L. V. Sayapina, S. V. Dentovskaya, R. Z. Shaikhudinova, S. A. Ageev, B. Lindner, A. N. Kondakova, N. A. Kocharova, S. N. Senchenkova, O. Holst, G. B. Pier, Y. A. Knirel, A. P. Anisimov, V. L. Motin</i>	
DEVELOPMENT OF IMMUNIZATION STRATEGIES AGAINST LEISHMANIOSIS BASED ON THE LEISHMANIA HISTONES PATHOANTIGENS	101
<i>Javier Carrión, Cristina Folgueira, Carlos Alonso</i>	
NUCLEOSIDE HYDROLASE DNA VACCINE AGAINST CANINE VISCERAL LEISHMANIASIS	104
<i>Gp Borja-Cabrera, Fb Santos, E Picillo, Ae Gravino, L Manna, Cb Palatik-De-Sousa</i>	

LEPTOSPIROSIS VACCINE: SEARCH FOR SUBUNIT CANDIDATES	110
<i>S. R. Felix, É. F. Silva, S. D. D. Jouglard, D. M. Hartmann, A. A. Grassmann, O. A. Dellagostin</i>	
CLONING OF THE NUCLEOSIDE HYDROLASE OF LEISHMANIA DONOVANI AIMING AT THE DEVELOPMENT OF A SYNTHETIC VACCINE AGAINST VISCERAL LEISHMANIASIS	115
<i>D Nico, C Claser, Mm Rodrigues, Is Soares, Cb Palatnik-De-Sousa</i>	
THE NUCLEOSIDE HYDROLASE DNA VACCINE VR1012NH36 IN PROPHYLACTIC VACCINATION AGAINST MICE TEGUMENTAR LEISHMANIASIS	120
<i>L. O. P. Souza, C. B. Palatnik De Sousa</i>	
TISSUE VACCINES FOR PREVENTION AND TREATMENT OF PROSTATE CANCER	124
<i>M. A. Suckow, P. Hall, M. C. Hiles</i>	
INDUCTION OF ANTI-TUMOR IMMUNE RESPONSES WITH OLIGOMANNOSE-COATED LIPOSOMES TARGETING TO PERITONEAL MACROPHAGES	127
<i>Kunio Tsujimura, Yuzuru Ikehara, Toshi Nagata, Yukio Koide, Naoya Kojima</i>	
ADJUVANTED VACCINE COMPONENTS: ANALYSIS OF STRUCTURE AND STABILITY	135
<i>Marina Kirkitadze, Ankit Sinha, Jian Hu, Wayne Williams, George Cates</i>	
ADJUVANT FORMULATION FOR VETERINARY VACCINES: MONTANIDE™ GEL SAFETY PROFILE	140
<i>R. Parker, S. Deville, L. Dupuis, F. Bertrand, J. Aucouturier</i>	
LIPOSOME IN SITU GELLING SYSTEM: NOVEL CARRIER BASED VACCINE ADJUVANT FOR INTRANASAL DELIVERY OF RECOMBINANT PROTEIN VACCINE	148
<i>Shailja Tiwari, Amit K. Goyal, Neeraj Mishra, Bhuvaneshwar Vaidya, Abhinav Mehta, Devyani Dube, Suresh P. Vyas</i>	
INDUCTION OF IMMUNE RESPONSE OF HEPATITIS B VACCINE USING POLYESTER POLYMER AS AN ADJUVANT	164
<i>S. M. Sivakumar, N. Sukumaran</i>	
OBSTACLES IN THE MOTIVATION OF HEALTH CARE WORKERS FOR PERTUSSIS VACCINATION	174
<i>Sabine Wicker, Stefan Zielen, Markus A. Rose</i>	
VACCINE STABILITY MONITORING USING THE LIFETRACK® ELECTRONIC STABILITY MONITOR	177
<i>Stephen E. Zweig</i>	
CHALLENGES AND POTENTIAL SOLUTIONS TO INNOVATIVE VACCINE DEVELOPMENT FOR DEVELOPING COUNTRIES	183
<i>Julie Milstien</i>	
PNEUMOCOCCAL CONJUGATE VACCINES: WHAT DO WE KNOW AND WHAT DO WE NEED?	189
<i>Jennifer Schranz</i>	
A NEW METHOD FOR DEALING WITH ETHICAL ISSUES IN THE AREA OF VACCINES AND VACCINATION	206
<i>Ray Spier</i>	
Author Index	